Haynes, N. | bioRxiv Science

bioRxiv2026

Targeting DNA Methylation Reactivates Type I Interferon Signalling in Bone-Metastatic Breast Cancer

Bone metastasis remains a major clinical challenge in advanced breast cancer. Downregulation of type I interferon signalling, a critical immunomodulatory pathway in anti-cancer immunity and disease progression, is a defining feature of this process. Here, we utilised an IFN-reporter system to perform unbiased epigenetic compound screens to identify agents that could restore type I IFN signalling. This screen identified Decitabine, a DNA hypomethylating agent, that enhanced tumor immunogenicity across a broad range of mouse and human breast cancer cell lines, including bone-derived lines. Mechanistically, suppression of interferon-stimulated genes is highly correlated with elevated DNMT1 expression in bone metastasis compared with primary tumor, in both mouse models and matched human samples. Decitabine treatment was sufficient to reactivate interferon stimulated genes in bone-derived 4T1.2 cell lines via hypomethylation of type I interferon pathway gene promoter regions. Correspondingly, in the syngeneic 4T1.2 metastasis mouse model, Decitabine treatment conferred a survival benefit and reduced metastatic potential, particularly in bone. Our findings reveal DNA methylation as a key regulator of the transcriptional programs underlying bone metastasis, providing mechanistic insight into how Decitabine reactivates type I interferon signalling and reduces metastatic potential, highlighting epigenetic reprogramming as a promising approach for targeting metastatic breast cancer. STATEMENT OF SIGNIFICANCEBone metastasis remains a major clinical challenge and a key mechanism of progression to bone is the suppression of tumor-inherent type I interferon signalling. We identified Decitabine, a DNA hypomethylating agent, as a promising therapeutic agent to enhance tumor immunogenicity across a broad range of breast cancer cell lines, including bone metastasis-derived lines. Our findings support DNA methylation as a key regulator of transcriptional programs associated with bone metastatic progression, and provide mechanistic insight into how Decitabine reactivates type I interferon signalling and reduces metastatic potential in vivo. These results highlight epigenetic reprogramming as a promising approach for targeting metastatic breast cancer.

Cancer Biology↗

bioRxiv2025

Foundational Architecture Enabling Federated Learning for Training Space Biomedical Machine Learning Models between the International Space Station and Earth

The public and commercial space industries are planning longer duration and more distant space missions, including the establishment of a habitable lunar base and crewed missions to Mars. To support Earth-independent scientific and medical operations, such missions can leverage artificial intelligence and machine learning models to assist with crew healthcare, spacecraft maintenance, and other critical tasks. However, transferring large volumes of data between Earth and space for model development consumes valuable bandwidth, is vulnerable to communication disruptions, and may compromise crew safety and data privacy. Federated learning enables model training while keeping data in situ and only transferring model parameters. In this work, we present a flexible, resilient federated learning framework that provides the secure transmission of model updates between Earth and the International Space Station. On March 15, 2024, this framework pioneered the deployment of federated learning in a spaceflight setting, training classifier models between Earth and the ISS using both real biomedical research data and synthetically generated data.

bioinformatics↗